

# The BOLD-Specific Flow-Volume Relationship During Hypercapnia and Hypocapnia

J. J. Chen<sup>1</sup>, and G. B. Pike<sup>1</sup>

<sup>1</sup> McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada

## Introduction

Knowledge of the relationship between venous cerebral blood volume ( $\Delta\text{CBV}_v$ ) and blood flow ( $\Delta\text{CBF}$ ) changes is crucial to understanding the blood oxygenation level-dependent (BOLD) fMRI signal. To date, Grubb's power-law ( $\text{rCBV} = \text{rCBF}^\alpha$ ), where an  $\alpha$  of 0.38 was measured in rhesus monkeys under hypercapnic challenge [2], has been extensively used in human BOLD modeling. The equivalence of the flow-volume relationship observed under neuronal activation and hypercapnia has been further investigated using PET [3,4], and is instrumental in calibrated BOLD-based cerebral oxygen metabolism ( $\text{CMRO}_2$ ) estimation [1,5]. However, these previous measurements were of total  $\Delta\text{CBV}$  instead of the BOLD-specific venous  $\Delta\text{CBV}_v$ , and the venous flow-volume relationship under  $\text{CO}_2$ -induced flow changes needs to be measured for fMRI applications. In addition, the comparability of the venous flow-volume relationship under focal and  $\text{CO}_2$ -induced hyperemia has yet to be established. We found the former relationship in humans to be characterized by  $\alpha = 0.23$  [6], significantly lower than Grubb's value. In this work, we report on the venous flow-volume relationship in humans under graded hyper- and hypocapnia.

## Methods


All acquisitions were performed using a Siemens Trio 3 T system, involving 16 healthy adult subjects (age =  $25.8 \pm 3.5$  years, 9 females) who gave informed consent. The body and neurovascular coils were used for transmitting and receiving, with basic imaging parameters: FOV/matrix/#slices/slice-thickness/TR = 256 mm/64x64/1/5 mm/5 s. Changes in venous cerebral blood volume ( $\Delta\text{CBV}_v$ ) were measured using the venous-refocusing for volume-estimation (VERVE) technique [6,7], with CSF suppression performed at an inversion time (TI) of 1350 ms. In the VERVE magnetization preparation,  $\tau_{180} = 3$  ms and 24 ms, for fast and slow-refocusing, respectively. QUIPSS II arterial-spin labeling (ASL) [8], with scan parameters  $\text{TI}_1/\text{TI}_2/\text{TE}/\text{labeling thickness/gap} = 700$  ms/1300 ms/25 ms/150 mm/5 mm, was used to measure  $\Delta\text{CBF}$  (control-tag) and  $\Delta\text{BOLD}$  ((control+tag)/2). Mild and moderate hyper- and hypocapnia were induced through the administration of various mixtures of  $\text{O}_2$ ,  $\text{CO}_2$  and medical air delivered using the Respiract breathing circuit (Thornhill Research, Toronto, Canada) designed to provide computerized targeting of end-tidal  $\text{O}_2$  ( $\text{ETO}_2$ ) and  $\text{CO}_2$  ( $\text{ETCO}_2$ ) pressure independent based on the sequential gas delivery method [9]. This device significantly increases steady-state  $\text{ETO}_2$  stability while achieving  $\text{ETO}_2$  invariability relative to existing methods, thus enabling us to accurately assess steady-state flow-volume changes. The stimulation paradigm employed 2 repetitions of 60 s/180 s/120 s off/on/off blocks. The calibration from  $\Delta\text{VERVE}$  to  $\Delta\text{CBV}_v$  [7] was performed for each subject at each  $\text{ETCO}_2$  using *in vivo* jugular vein oximetry [10]. A 3D  $\text{T}_1$ -weighted scan served as anatomical reference, from which grey matter (GM) masks were extracted using parametric Bayesian segmentation. The region-of-interest (ROI) was delineated for each subject by thresholding the BOLD  $t$ -map at  $P < 0.05$  (corrected for multiple comparisons). The overlap between these BOLD ROIs and the GM mask was used to calculate average  $\Delta\text{CBF}$  (%) and  $\Delta\text{CBV}_v$  (%) in steady-state, defined to begin 90 s after the onset and offset of the challenge in order to accommodate the slower hypocapnic transition. Finally,  $\alpha$  was estimated using unconstrained non-linear least-square curve-fitting weighted by the inverse standard deviation of the data points.

## Results


The average baseline venous oxygenation ( $Y_0$ ) was  $60.6 \pm 11.4\%$ . The steady-state  $\Delta\text{CBF}$  and  $\Delta\text{CBV}_v$  and BOLD time courses in cortical GM for one subject during a moderate hypercapnia ( $\Delta\text{ETCO}_2 = 9 \pm 0.8$  mmHg) challenge are shown in Figure 1, with each symbol representing one sessional average from each subject. Mild and moderate hypercapnia trials produced average  $\Delta\text{ETCO}_2$  of  $4.6 \pm 0.9$  and  $9.1 \pm 1.1$  mmHg, respectively, while mild and moderate hypocapnia trials produced average  $\Delta\text{ETCO}_2$  of  $-3.4 \pm 1.2$  and  $-5.7 \pm 2.4$  mmHg, respectively, with steady-state stability maintained. A scatter plot of  $\text{rCBV}_v$  vs.  $\text{rCBF}$  is shown in Fig. 2. Since the power-law fit for cortical and sub-cortical ROIs ( $P < 0.001$  for both cases) were not significantly different ( $P > 0.05$ ), the two regions were combined in the final weighted fit, which resulted in  $\alpha = 0.19 \pm 0.04$ , with  $P < 0.001$ . Linearization of the fit yielded  $R = 0.52$ ,  $r^2 = 0.38$ .

## Conclusion

Using venous CBV changes, the estimated power-law coefficient ( $\alpha = 0.19 \pm 0.04$ ), in agreement with our previous findings for human neuronal activation ( $\alpha = 0.23 \pm 0.05$ ) [6]. Thus, as was in the case of total  $\Delta\text{CBV}$  [3,4], the venous flow-volume relationships observed under hypercapnia as well as hypocapnia were found to be equivalent to that for neuronal activation. However, this  $\alpha$  value is significantly lower than Grubb's value of 0.38. Our results are in agreement with animal  $\Delta\text{CBV}_v$  data under hypercapnia [11]. Thus, since BOLD is mainly dependent on venous  $\Delta\text{CBV}_v$ , the flow-volume relationship given by Grubb's  $\alpha$  of 0.38 overestimates the CBV contribution to hypercapnia-induced BOLD. This leads to overestimation of the maximum achievable BOLD signal in calibrated BOLD, resulting in the underestimation of activation-induced  $\Delta\text{CMRO}_2$ .



**Figure 1.** The top 2 plots show  $\text{ETCO}_2$  and  $\text{ETO}_2$  tracings corresponding to the BOLD, CBF and  $\text{CBV}_v$  measurements (bottom 3 plots) obtained from the grey-matter constrained BOLD  $t$ -map ROI for one subject during blocks of  $\text{ETCO}_2$  increase by 9 mmHg, indicated by the shaded regions.  $\text{ETO}_2$  remained unchanged during  $\text{ETCO}_2$  manipulations.



**Figure 2.** The  $\text{rCBF}$  and  $\text{rCBV}$  measurements and the resulting fit to the power-law (black line), where  $\alpha = 0.19 \pm 0.04$ . Each symbol represents one sessional average from one subject. Triangles and circles indicate cortical and sub-cortical data, respectively, and the colours represent the trial number. Red and blue = low and moderate hypercapnia, respectively, while black = moderate hypocapnia. The shaded region represents the 95% confidence interval of the fit.

## References

- [1] Hoge RD et al. Magn Reson Med;42:849-63; [2] Grubb RL et al. Stroke;5:630-9; [3] Ito H et al. J CBF Metab; 21:608-12; [4] Ito et al. J CBF Metab;23:665-70; [5] Davis TL et al. PNAS;95:1834-9; [6] Chen JJ and Pike GB, ISMRM 2008; p1909; [7] Stefanovic B and Pike GB, Magn Reson Med;53:339-47; [8] Wargin JM and Pike GB, Magn Reson Med;52:1190-9; [9] Slessarev M et al. J Physiol;581:1207-19; [10] Foltz WD et al. Magn Reson Med;42:837-48; [11] Lee SP et al. Magn Reson Med;45:791-800;